Subscribe

News
Media
Conferences
Publications
Events
CE
Resources
Subscribe

Spotlight -

Community/Retail|

Pharmacy Technician|

Danny Rischin, MD

Articles by Danny Rischin, MD

Understanding Second Primary Tumors in C-POST: Definitions, Incidence, and Clinical Implications of Cemiplimab

ByDanny Rischin, MD,Aislinn Antrim, Managing Editor

November 16th 2025

Danny Rischin, MD, reviews findings from the C-POST trial.

Latest Updated Articles

Trending on Pharmacy Times

A Common Virus May Hold New Clues to Lupus

Expert Discusses Logistical Considerations and Future Research Needs for Radiopharmaceuticals

Zongertinib Shows Clinically Meaningful Efficacy in Advanced HER2-Mutant NSCLC

Understanding Second Primary Tumors in C-POST: Definitions, Incidence, and Clinical Implications of Cemiplimab

SHR-A1811 Plus Pertuzumab Improves Survival in HER2-Positive Metastatic Breast Cancer

© 2025 MJH Life Sciences^®

All rights reserved.